` PCRX (Pacira Biosciences Inc) vs S&P 500 Comparison - Alpha Spread

PCRX
vs
S&P 500

Over the past 12 months, PCRX has underperformed S&P 500, delivering a return of -14% compared to the S&P 500's 12% growth.

Stocks Performance
PCRX vs S&P 500

Loading
PCRX
S&P 500
Add Stock

Performance Gap
PCRX vs S&P 500

Loading
PCRX
S&P 500
Difference

Performance By Year
PCRX vs S&P 500

Loading
PCRX
S&P 500
Add Stock

Competitors Performance
Pacira Biosciences Inc vs Peers

S&P 500
PCRX
LLY
JNJ
NOVO B
ROG
Add Stock

Pacira Biosciences Inc
Glance View

Market Cap
1.2B USD
Industry
Pharmaceuticals

Pacira Biosciences, Inc. is a holding company, which provide non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. The company is headquartered in Tampa, Florida and currently employs 697 full-time employees. The company went IPO on 2011-02-03. The firm is focused on the development, manufacture, marketing, distribution and sale of non-opioid pain management and regenerative health solutions. Its product candidate, EXPAREL (bupivacaine liposome injectable suspension) provides postsurgical analgesia and reduces the consumption of opioid medications. EXPAREL consists of bupivacaine, an amide-type local anesthetic, encapsulated in DepoFoam, an extended-release drug delivery technology, that delivers bupivacaine over time for extended analgesia. Its ZILRETTA (triamcinolone acetonide extended-release injectable suspension) is an extended-release, intra-articular, injection indicated for the management of osteoarthritis knee pain. Its iovera is a handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.

PCRX Intrinsic Value
63.391 USD
Undervaluation 59%
Intrinsic Value
Price
Back to Top